Alterity Therapeutics Ltd has released a press release.
New Publication Demonstrates ATH434 is Neuroprotective
Filed with ASX ·
6ix hasn’t read this filing yet.
Alterity Therapeutics Ltd. on 6ix
Earlier from Alterity Therapeutics
- New US patent targeting major neurodegenerative diseases
- EU Regulatory Guidance for ATH434 Phase 2 Clinical Trial
- ATH434 protects brain cells and improves motor function
- Alterity to present at Global Life Science Conference
- Michael J Fox grant for Parkinsons research on ATH434
Later from Alterity Therapeutics
- New US Patent Expands Neurodegeneration Treatment Portfolio
- Appendix 4E & Annual Report 2021
- Form 20-F
- Expanded ATH434 Phase 2 Clinical Development Program
- New Data Advance ATH434 as Neurodegeneration treatment
Follow Alterity Therapeutics into a list and get an email when it puts out news.
Follow Alterity Therapeutics